GMAB jumps as Genmab posts positive Phase 3 lymphoma data

Genmab A/S (GMAB) is up 12.3% today. Here is some analysis on what might have caused this price movement. ([rss.globenewswire.com](https://rss.globenewswire.com/news-release/2026/10/05/3374942/0/en/genmab-and-abbvie-announce-epcoritamab-in-combination-with-r-chop-demonstrates-statistically-significant-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-d.html))

Analysis: The clearest catalyst appears to be Genmab’s October 5 announcement of positive topline Phase 3 results for epcoritamab plus R-CHOP in newly diagnosed diffuse large B-cell lymphoma. The move may also be getting an extra lift from positive Phase 2 ovarian cancer data released two days earlier, which added to broader optimism around the company’s late-stage pipeline. ([rss.globenewswire.com](https://rss.globenewswire.com/news-release/2026/10/05/3374942/0/en/genmab-and-abbvie-announce-epcoritamab-in-combination-with-r-chop-demonstrates-statistically-significant-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-d.html))

Details:

Genmab and its partner said the Phase 3 EPCORE DLBCL-2 study met its primary endpoint, showing a statistically significant improvement in progression-free survival versus R-CHOP alone. ([rss.globenewswire.com](https://rss.globenewswire.com/news-release/2026/10/05/3374942/0/en/genmab-and-abbvie-announce-epcoritamab-in-combination-with-r-chop-demonstrates-statistically-significant-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-d.html))

The company said the combination reduced the risk of disease progression or death by 51% in the studied patient group, a result that suggests meaningful frontline potential for epcoritamab. ([rss.globenewswire.com](https://rss.globenewswire.com/news-release/2026/10/05/3374942/0/en/genmab-and-abbvie-announce-epcoritamab-in-combination-with-r-chop-demonstrates-statistically-significant-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-d.html))

Genmab said the safety profile was generally well tolerated and consistent with the known profiles of the individual medicines, which likely helped investor confidence around the readout. ([rss.globenewswire.com](https://rss.globenewswire.com/news-release/2026/10/05/3374942/0/en/genmab-and-abbvie-announce-epcoritamab-in-combination-with-r-chop-demonstrates-statistically-significant-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-d.html))

Genmab had also announced positive Phase 2 RAINFOL-01 results for Rina-S in platinum-resistant ovarian cancer on October 3, giving investors a second recent pipeline update to focus on. ([ir.genmab.com](https://ir.genmab.com/genmab-news/))

Sources:

Genmab, SEC, GlobeNewswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive GMAB Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$GMAB Hedge Fund Activity

We have seen 148 institutional investors add shares of $GMAB stock to their portfolio, and 120 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

DEERFIELD MANAGEMENT COMPANY, L.P. added 6,865,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $188,581,550
PARADIGM BIOCAPITAL ADVISORS LP added 5,165,295 shares (+64.8%) to their portfolio in Q2 2026, for an estimated $141,890,653
SOFINNOVA INVESTMENTS, INC. added 3,292,954 shares (+437.7%) to their portfolio in Q2 2026, for an estimated $90,457,446
DEEP TRACK CAPITAL, LP added 1,986,750 shares (+54.2%) to their portfolio in Q2 2026, for an estimated $54,576,022
ORBIS ALLAN GRAY LTD removed 1,557,417 shares (-12.0%) from their portfolio in Q2 2026, for an estimated $42,782,244
TWO SIGMA INVESTMENTS, LP added 1,167,411 shares (+49.9%) to their portfolio in Q2 2026, for an estimated $32,068,780
QUBE RESEARCH & TECHNOLOGIES LTD added 1,011,938 shares (+149.4%) to their portfolio in Q2 2026, for an estimated $27,797,936

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.